Epithalon and Epitalon names
FDA's Substance Registry lists Epithalon as a synonym of Epitalon. Its separate July 2026 briefing describes epitalon free base as a synthetic four-amino-acid peptide. The spelling connection helps match sources, while the free-base qualification identifies the material described in the assessment. FDA Epitalon terminology record, FDA epitalon assessment.
The Epithalon vial page lists 10mg / 50mg variants. Those are catalogue amounts, not a concentration or a clinical schedule. Neither the synonym record nor a mass expression independently verifies which chemical form or formulation is present in a supplier vial. FDA Epitalon terminology record, FDA epitalon assessment.
Telomerase and telomere cell research
A 2003 study exposed telomerase-negative human fetal fibroblast cultures to Epithalon and reported telomerase activity and telomere elongation. These were human-derived cells in culture, not a clinical trial measuring aging outcomes in people. Epithalon cell-culture study.
The experiment therefore supplies a concrete cellular result. Telomerase activity and telomere elongation are the reported endpoints; longer human life was not the outcome measured in that cell-culture experiment. Epithalon cell-culture study.
Compounded epitalon safety concerns
FDA's compounding safety communication identifies aggregation, peptide-related impurities and potential immune-response concerns for compounded epitalon. These concerns apply to the compounded substance discussed in that communication; they do not independently verify the formulation or safety of this supplier vial. FDA compounding safety communication.
The Epithalon Pen has 10mg / 50mg catalogue variants, separately documented from the vial. The shared name and amounts do not establish equivalent formulation or performance.
